Literature DB >> 9648041

Examination of DSM-IV criteria for attention deficit/hyperactivity disorder in a county-wide sample.

M L Wolraich1, J N Hannah, A Baumgaertel, I D Feurer.   

Abstract

This study replicated, in the subsequent academic year, teacher-reported prevalence rates for attention deficit/hyperactivity disorder (ADHD) based on DSM-IV. Teachers in grades K-5 in a Tennessee county (10 schools, 214 teachers, and 4323 children) completed questionnaires on all their students consisting of the DSM-IV symptoms for disruptive behavior disorders, except for eight conduct disorders symptoms, seven symptoms screening for anxiety or depression, ratings of performance, and questions about the presence of ADHD, stimulant medication treatment, and behavioral or academic problems. The prevalence rates were 16.1% for ADHD-all types, 8.8% for ADHD-inattentive type (AD), 2.6% for ADHD-hyperactive/impulsive type (HI), and 4.7% for ADHD-combined type and 6.8, 3.2, 0.6, and 2.9%, respectively, when impairment was taken into consideration. The rates of problems differed mostly between ADHD-AD AND ADHD-HI (30% vs. 68%) for behavior and (56% vs. 16%) for academics. Few (11-33%) had an ADHD diagnosis or were treated with stimulant treatment (8-26%). DSM-IV criteria are likely to increase the prevalence but may better characterize the heterogeneity of this disorder.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9648041     DOI: 10.1097/00004703-199806000-00003

Source DB:  PubMed          Journal:  J Dev Behav Pediatr        ISSN: 0196-206X            Impact factor:   2.225


  44 in total

1.  The worldwide prevalence of ADHD: is it an American condition?

Authors:  Stephen V Faraone; Joseph Sergeant; Christopher Gillberg; Joseph Biederman
Journal:  World Psychiatry       Date:  2003-06       Impact factor: 49.548

2.  The shifting subtypes of ADHD: classification depends on how symptom reports are combined.

Authors:  Andrew S Rowland; Betty Skipper; David L Rabiner; David M Umbach; Lil Stallone; Richard A Campbell; Richard L Hough; A J Naftel; Dale P Sandler
Journal:  J Abnorm Child Psychol       Date:  2008-03-18

3.  Cross-cultural reliability and validity of ADHD assessed by the ADHD Rating Scale in a pan-European study.

Authors:  Manfred Döpfner; Hans-Christoph Steinhausen; David Coghill; Søren Dalsgaard; Lynne Poole; Stephen J Ralston; Aribert Rothenberger
Journal:  Eur Child Adolesc Psychiatry       Date:  2006-12       Impact factor: 4.785

4.  Life in the last lane.

Authors:  John D Grant
Journal:  Paediatr Child Health       Date:  2002-12       Impact factor: 2.253

5.  A randomized trial of two promising computer-based interventions for students with attention difficulties.

Authors:  David L Rabiner; Desiree W Murray; Ann T Skinner; Patrick S Malone
Journal:  J Abnorm Child Psychol       Date:  2010-01

6.  Callous-Unemotional Traits are Uniquely Associated with Poorer Peer Functioning in School-Aged Children.

Authors:  Sarah M Haas; Stephen P Becker; Jeffery N Epstein; Paul J Frick
Journal:  J Abnorm Child Psychol       Date:  2018-05

7.  The Role of Parental ADHD in Sustaining the Effects of a Family-School Intervention for ADHD.

Authors:  Anne E Dawson; Brian T Wymbs; Stephen A Marshall; Jennifer A Mautone; Thomas J Power
Journal:  J Clin Child Adolesc Psychol       Date:  2014-12-13

8.  Teachers' screening for attention deficit/hyperactivity disorder: comparing multinational samples on teacher ratings of ADHD.

Authors:  Mark L Wolraich; E Warren Lambert; Anna Baumgaertel; Santiago Garcia-Tornel; Irene D Feurer; Leonard Bickman; Melissa A Doffing
Journal:  J Abnorm Child Psychol       Date:  2003-08

Review 9.  Pharmacology and pharmacogenetics of pediatric ADHD with associated aggression: a review.

Authors:  Bianca D Patel; Drew H Barzman
Journal:  Psychiatr Q       Date:  2013-12

10.  Treatment Effects of a Primary Care Intervention on Parenting Behaviors: Sometimes It's Relative.

Authors:  Anne Shaffer; Oliver Lindhiem; David Kolko
Journal:  Prev Sci       Date:  2017-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.